Nature Communications · 2018 · 35 citations · 59 references
MedicineCancer BiologyOncologyCell SignalingMetastasisMolecular OncologyCancer Cell SignalingCytokine BiologyCytokine SignalingInflammatory SignalingOncogenic Signaling PathwaysSignal Transduction In CancerCytokine Signaling In CancerCytokine Signaling In TumorsInflammation-driven ProgressionInflammation-driven Tumor ProgressionInterleukin-1 Beta SignalingNf-κb SignalingTumor-associated CytokinesTumor-associated Inflammation
Malignant pleural effusion (MPE) is a frequent metastatic manifestation of human cancers. While we previously identified KRAS mutations as molecular culprits of MPE formation, the underlying mechanism remained unknown. Here, we determine that non-canonical IKKα-RelB pathway activation of KRAS-mutant tumor cells mediates MPE development and this is fueled by host-provided interleukin IL-1β. Indeed, IKKα is required for the MPE-competence of KRAS-mutant tumor cells by activating non-canonical NF-κB signaling. IL-1β fuels addiction of mutant KRAS to IKKα resulting in increased CXCL1 secretion that fosters MPE-associated inflammation. Importantly, IL-1β-mediated NF-κB induction in KRAS-mutant tumor cells, as well as their resulting MPE-competence, can only be blocked by co-inhibition of both KRAS and IKKα, a strategy that overcomes drug resistance to individual treatments. Hence we show that mutant KRAS facilitates IKKα-mediated responsiveness of tumor cells to host IL-1β, thereby establishing a host-to-tumor signaling circuit that culminates in inflammatory MPE development and drug resistance.
59
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin, Ignacio Arganda‐Carreras, Erwin Frise et al. · Nature Methods · 2012 · 70.9K citations
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie, Pablo Tamayo, Jesse S. Boehm et al. · Nature · 2009 · 4.2K citations · Full text